Antengene Corporation Limited

6996 · HKEX

Public Market Listing

6996HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Antengene Corporation Limited are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
4Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
XPO1 (exportin-1)Small molecule
Multiple MyelomaMyelofibrosisEndometrial Cancer
Phase 2
mTOR (inhibitor)Small molecule
Non-Small Cell Lung Cancer

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
SelinexorPhase 2/3Relapsed/Refractory Diffuse Large B-cell Lymphoma
Est. primary completion 2026-12 · NCT04442022 · CT.gov ↗
What to watch
2027 (2)
April 2027 (1)
SelinexorPhase 1/2Multiple Myeloma
Est. primary completion 2027-04 · NCT02343042 · CT.gov ↗
What to watch
June 2027 (1)
SelinexorPhase 2Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia
Est. primary completion 2027-06 · NCT05980806 · CT.gov ↗
What to watch
2028 (1)
January 2028 (1)
SelinexorPhase 2Multiple Myeloma, Refractory
Est. primary completion 2028-01 · NCT04414475 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(10)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

28 June 2027FDA action dateSelinexorPDUFA date for the XPOVIO plus ruxolitinib sNDA in myelofibrosis
US, FDA · Source ↗

Recent

17 November 2026Filing acceptedSelinexorFDA accepts the XPOVIO plus ruxolitinib sNDA in myelofibrosis
US, FDA · Source ↗
31 August 2026Filing submittedSelinexor (Xpovio)Karyopharm submits an sNDA to FDA for XPOVIO plus ruxolitinib in myelofibrosis (accelerated approval, Priority Review requested)
US, FDA · Karyopharm Therapeutics Inc. · Source ↗
30 July 2026Topline resultSelinexor (Xpovio)Phase 3 XPORT-EC-042 (NCT05611931) of selinexor maintenance in endometrial cancer did not meet its PFS primary endpoint
Global · Karyopharm Therapeutics Inc. · Source ↗
2 June 2026Topline resultSelinexorSENTRY Phase 3 topline results were mixed
24 March 2026Topline resultSelinexor (Xpovio)Phase 3 SENTRY (NCT04562389) met its first co-primary endpoint (SVR35) and missed its second (Abs-TSS)
Global · Karyopharm Therapeutics Inc. · Source ↗
March 2026WithdrawalSelinexorAccelerated approval in DLBCL voluntarily withdrawn at the FDA's request
US, FDA · Source ↗
16 December 2025ApprovalSelinexorMalaysia approves XPOVIO (selinexor) sNDA for relapsed/refractory DLBCL
MY, NPRA · Source ↗
5 March 2025ApprovalSelinexorXPOVIO approved in Indonesia
ID, BPOM · Source ↗
9 December 2024Topline resultSelinexorBENCH Phase III primary analysis presented: primary endpoint met

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$7.3M$11M$111M$5.3Mreport ↗

Annual history (1 year)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$13M—$123M$11Mreport ↗

Antengene Corporation Limited reported revenue of $12.8M, cash and equivalents of $123.34M, and a net loss of $44.43M for fiscal year 2024.

Figures only: this period's report disclosed no narrative text